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defective myocellular copper regulation and both
defects are rectified by divalent copper chelation
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Background: Heart disease is the leading cause of death in diabetic patients, and defective copper metabolism
may play important roles in the pathogenesis of diabetic cardiomyopathy (DCM). The present study sought to
determine how myocardial copper status and key copper-proteins might become impaired by diabetes, and how
they respond to treatment with the Cu (II)-selective chelator triethylenetetramine (TETA) in DCM.
Methods: Experiments were performed in Wistar rats with streptozotocin (STZ)-induced diabetes with or without
TETA treatment. Cardiac function was analyzed in isolated-perfused working hearts, and myocardial total copper
content measured by particle-induced x-ray emission spectroscopy (PIXE) coupled with Rutherford backscattering
spectrometry (RBS). Quantitative expression (mRNA and protein) and/or activity of key proteins that mediate
LV-tissue-copper binding and transport, were analyzed by combined RT-qPCR, western blotting, immunofluorescence
microscopy, and enzyme activity assays. Statistical analysis was performed using Student’s t-tests or ANOVA and
p-values of < 0.05 have been considered significant.
Results: Left-ventricular (LV) copper levels and function were severely depressed in rats following 16-weeks’ diabetes,
but both were unexpectedly normalized 8-weeks after treatment with TETA was instituted. Localized myocardial copper
deficiency was accompanied by decreased expression and increased polymerization of the copper-responsive
transition-metal-binding metallothionein proteins (MT1/MT2), consistent with impaired anti-oxidant defences and
elevated susceptibility to pro-oxidant stress. Levels of the high-affinity copper transporter-1 (CTR1) were depressed in
diabetes, consistent with impaired membrane copper uptake, and were not modified by TETA which, contrastingly,
renormalized myocardial copper and increased levels and cell-membrane localization of the low-affinity copper
transporter-2 (CTR2). Diabetes also lowered indexes of intracellular (IC) copper delivery via the copper chaperone for
superoxide dismutase (CCS) to its target cuproenzyme, superoxide dismutase-1 (SOD1): this pathway was rectified by
TETA treatment, which normalized SOD1 activity with consequent bolstering of anti-oxidant defenses. Furthermore,
diabetes depressed levels of additional intracellular copper-transporting proteins, including antioxidant-protein-1
(ATOX1) and copper-transporting-ATPase-2 (ATP7B), whereas TETA elevated copper-transporting-ATPase-1 (ATP7A).
(Continued on next page)* Correspondence: g.cooper@auckland.ac.nz
1The School of Biological Sciences, Faculty of Science, University of Auckland,
Auckland, New Zealand
2The Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science,
University of Auckland, Auckland, New Zealand
Full list of author information is available at the end of the article
© 2014 Zhang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zhang et al. Cardiovascular Diabetology 2014, 13:100 Page 2 of 18
http://www.cardiab.com/content/13/1/100(Continued from previous page)
Conclusions: Myocardial copper deficiency and defective cellular copper transport/trafficking are revealed as key
molecular defects underlying LV impairment in diabetes, and TETA-mediated restoration of copper regulation provides
a potential new class of therapeutic molecules for DCM.
Keywords: Diabetic cardiomyopathy, Copper-deficiency cardiomyopathy, Left-ventricular dysfunction, Myocellular
copper, Copper transporters, Superoxide dismutase 1, Copper chaperones, Cu (II)-chelation, Copper metalation,
Heart failureBackground
Cardiovascular disease is the leading cause of disability
and death in patients with diabetes mellitus [1,2], in whom
it is frequently accompanied by impaired LV function and
heart failure [3,4]. Hyperglycemia is a major factor for the
development of diabetic cardiomyopathy (DCM) which
contributes substantially to morbidity and mortality [5-7].
DCM causes numerous pathological changes, for example
myocellular hypertrophy, interstitial fibrosis and defective
fuel utilization, accompanied by damage to myocellular or-
ganelles including the plasma membrane, contractile ap-
paratus, mitochondria, and sarcoplasmic reticulum: these
defects cooperate to cause impaired systolic and diastolic
function and frequently progress to overt heart failure
[7-12]. The molecular mechanisms by which these defects
occur are poorly understood and currently there is no dir-
ectly effective treatment for DCM [3,7].
Pathogenetic mechanisms that cause tissue damage in
diabetes may reflect molecular defects that lead to in-
creased cellular production of superoxide anion (O2
●-) in
affected tissues [13,14]: examples are excessive O2
●- pro-
duction through mitochondrial dysfunction [15] coupled
with diminished O2
●- clearance through impaired SOD
activity (reviewed in [16]). In addition, alterations in ion
homeostasis have also been implicated in the pathogen-
esis of DCM [7,17]. For example, decreased myocellular
Ca2+ efflux through the Na+-Ca2+ exchanger (NCX) and
Ca2+-ATPase (SERCA) pump systems, has been linked
to defects in cardiac energy metabolism and contractile
function [17,18]; however, impaired calcium homeostasis
may not explain the contractile deficit in DCM [9,10].
Altered myocellular [K+]IC and [Na
+]IC may also contrib-
ute to the impaired cardiac function and energy-inefficient
metabolism in DCM [19,20].
Both copper deficiency [21,22] and copper excess states
[23] can cause elevated oxidative stress and impaired anti-
oxidant defenses [24,25]. Copper deficiency can cause
neurodegeneration [26], and hematological and cardiovas-
cular disorders [22], whereas copper overload may be ac-
companied by hepatic and neurological diseases [27,28].
Copper homeostasis is coordinated by several regulatory
protein chaperones, through which it is delivered to spe-
cific subcellular compartments and/or copper-requiring
proteins without releasing free copper atoms that couldotherwise damage cells and tissues [29,30]: examples in-
clude the copper chaperone for superoxide dismutase
(CCS) for SOD1, and the antioxidant 1 copper chaperone
(ATOX1) for ATP7A and ATP7B. Disturbances in copper
homeostasis have pronounced deleterious effects on many
bodily functions, such as those observed in Menkes’ or
Wilson’s diseases, which are caused by mutations in the
genes encoding ATP7A and ATP7B respectively [27,31].
In addition, copper is a key cofactor for many important
enzymes such as Cu/Zn-SOD (SOD1) [32], EC-SOD
(SOD3) [33], cytochrome c oxidase (COX) [34], and ceru-
loplasmin/ferroxidase [35], whereof deficient activities
have been implicated in the causation of several disease
states [36-38]. It has also been shown that localized
myocardial copper deficiency, caused by the heart-specific
knockout of Ctr1 in mice, causes severe cardiomyopathy
[39], as do genetically-mediated defects in humans and ro-
dents of the SCO2 gene, which encodes a chaperone pro-
tein necessary for copper metalation of the CuA site on
the COII subunit of COX [40,41]. These observations
provide key evidence linking myocardial copper deficiency
and impaired copper metalation to the causation of
cardiomyopathy.
Copper deficiency causes cardiomyopathy in several
animal species [42,43], wherein its pathobiology closely
resembles that of DCM [24,42,43]. However, indexes of
systemic copper regulation differ markedly between the
two conditions. Animals with cardiomyopathy caused by
insufficient copper intake exhibit clear signs of systemic
copper deficiency, including hypocupremia, hypocerulo-
plasminemia, anemia and neutropenia, and deficient
hepatic copper levels [44], all of which can be alleviated
by copper replacement. By contrast, diabetic animals
and patients with DCM show signs of systemic copper
excess with elevations in urinary copper and copper bal-
ance, normal or elevated plasma copper and ceruloplas-
min levels [8,16,45,46], and markedly elevated hepatic
and renal copper levels [46,47]. These observations indi-
cate that impaired copper metabolism occurs in dia-
betes, and that defective copper regulation could play
specific roles in the pathogenesis and progression of the
diabetic complications.
It has previously been shown that Cu (II) chelation with
triethylenetetramine (TETA) restores indexes of systemic
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with LV hypertrophy [48], and improves cardiac struc-
ture and function in rat models of diabetes [8,10,49,50].
The current study was designed to investigate the ef-
fects of diabetes on copper status and indexes of myo-
cellular copper transport/trafficking, and their potential
contribution to the development of heart disease in a
widely-accepted rat model of DCM. We also investi-
gated the molecular mechanisms by which TETA treat-
ment ameliorates diabetes-induced dysregulation of cardiac
copper homeostasis, which could contribute to observed
TETA-mediated improvement in cardiac function. We
compared myocardial expression (mRNA and protein) of
key components of the cellular copper-transport pathways,
which coordinate the regulation of copper homeostasis in
cardiac LV tissues, in groups of non-diabetic control, dia-
betic, and TETA-treated-diabetic animals; we also under-
took some studies in TETA-treated non-diabetic animals
for comparative purposes (Table 1). We also examined the
effects of TETA treatment on the expression and cellular
translocation of copper-transporter proteins and copper-
enzymes. In addition, we measured changes in LV-copper
content and its response to TETA treatment, in relation to
alterations in the expression/activity of copper-regulatory
proteins in rats with DCM.
Methods
Animal studies
Protocols for the induction of diabetes in rats and TETA
treatment were as previously described [8,49]. Diabetes
was induced by a single intravenous injection of STZ
(55 mg/kg body-weight; Sigma) into the tail-veins of adult
male Wistar rats (6–7 weeks of age; 220–250 g); controlTable 1 Relevant experimental group characteristics and hem





Age at enrolment (weeks) 6-7
Age when studied (weeks) 22-23
Body weight (g) 573 ± 16
Blood glucose (mM) 5.8 ± 0.20
Heart weight (g) 1.58 ± 0.04
Heart-weight/Body-weight (×10−3) 2.76 ± 0.01
Cardiac output (ml/min) 79.2 ± 3.2
LV + dP/dt max (mmHg/s) 4506 ± 549
LV -dP/dt min (mmHg/s) −4384 ± 453
Measurements of steady-state cardiac function were made at 20 cm-H2O preload a
SEM. Data were analyzed using two-way ANOVA with post-hoc Tukey’s tests: *P < 0.0animals received a saline injection instead of STZ. TETA
was administered via the drinking water (20 mg/day per
rat, Fluka), beginning at 8 weeks after saline or STZ injec-
tion. LV tissues from each treatment group (non-diabetic
control, diabetic, TETA treated-control and TETA treated-
diabetic) were collected after 8-weeks’ treatment. All ex-
perimental protocols were approved by the Animal Ethics
Committee of the University of Auckland. The study was
performed according to the ‘Guide for the Care and Use of
Laboratory Animals’ [51], and this manuscript is consist-
ent with the ‘ARRIVE guidelines for the reporting of ani-
mal research’ [52].Choice of TETA dosage
The dosage used here was based on those employed in
known clinical applications of TETA (as TETA dihy-
drochloride or trientine) in the treatment of patients with
Wilson’s disease, and for the experimental therapy of dia-
betes [10]. In brief, dosages employed for the treatment
of Wilson’s disease in adults typically vary from 750–
2000 mg/day (equivalent to ~11-29 mg/kg-day in 70-kg
adults) [53]. Here, we administered TETA dihydrochloride
in the drinking water to diabetic rats at 20 mg/day (equiva-
lent to ~68 mg/kg-day of trientine in 250-g rats). This dos-
age is supported by our published dose-rising phase-1
clinical trial, where we showed that dosages of 1200 and
3600 mg/day (equivalent to ~17 and 51 mg/kg-day in 70-
kg adults) were effective and well tolerated in healthy adult
human volunteers [54], and also by our phase-2 trial where
1200 mg/day of trientine (~17 mg/kg-day in 70-kg adults)
administered for 12 months markedly improved LV mass








562 ± 17 220 ± 9* 290 ± 21*
5.1 ± 0.15 29.8 ± 0.65* 27.0 ± 1.20*
1.63 ± 0.05 1.03 ± 0.06* 1.18 ± 0.09*
2.77 ± 0.13 4.66 ± 0.13* 4.08 ± 0.17*#
75.0 ± 3.5 53.3 ± 8.1* 78.0 ± 4.0#
4667 ± 417 2249 ± 162* 4082 ± 196#
−4245 ± 413 −1952 ± 144* −3366 ± 125#
nd 75 mmHg afterload of hearts paced at 300 beats/min. Values are means ±
5 vs control; #P < 0.05 vs diabetic.
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We have extensively validated the STZ-based model we
chose to employ here by showing that these diabetic rats
respond both to untreated diabetes and following TETA
treatment, in ways that closely reflect responses in pa-
tients with T2D [8,10,16,45,48,49,55]. To date, we have
shown that TETA treatment exerts substantial effects to
restore LV mass in patients with LV hypertrophy [48],
similar to its effects in rats [8,49], and that the dosage-
responsiveness of TETA-mediated removal of copper
from the body is similar in rats [8] and human volun-
teers [54,56]. These findings provide strong support for
our use of this model for the current studies.
Measurement of ex-vivo cardiac function
We measured cardiac function in isolated, ex-vivo perfused
working hearts, as previously detailed [8,49]. On the ex-
perimental day, rats were anesthetized (isoflurane), hepa-
rinized (1,000 IU/kg i.v.), and hearts excised and immersed
in 4°C Krebs-Henseleit bicarbonate buffer (KHB). Retro-
grade (Langendorff) perfusion was established (KHB, 37°C,
gassed with O2:CO2 95:5 (vol/vol). Working-mode perfu-
sion was then established (preload, 10 cmH2O; afterload,
55.9 mmHg) with pacing (300 bpm; Digitimer). Intra-
chamber LV pressure (SP855; AD Instruments), aortic
pressure (PX23XL, Stratham Gould), and aortic (Transonic
T206) and coronary flows were measured; pressure and
flow data were recorded (Powerlab16s, ADI); and the max-
imum rate of ventricular pressure development (+dPLV/dt)
and minimum rate of relaxation (−dPLV/dt) were derived.
Atrial filling pressure was decreased (to 5 cmH2O) and
then increased (in seven equal steps of 2.5 cmH2O to 20
cmH2O [final]), and 1-min averages were extracted. Filling
pressure was then fixed at 10 cmH2O, and afterload at
75 mmHg.
Measurement of tissue copper content
Copper concentrations were determined in dry ex vivo
LV-tissue by using a reference method, PIXE coupled with
RBS [57]. The calibration, measurements, and limits of de-
tection were based on the areas of the Kα x-ray peaks as
measured by the software package GUPIX Elemental, and
concentrations were extracted from PIXE spectra using
GUPIX software (University of Guelph, ON, Canada), as
previously described [10,46].
Measurement of mRNA by RT-qPCR
Here, RT-qPCR was performed according to ‘The Mini-
mum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE)’ guidelines [58]. Total
RNA was extracted from rat LV tissues that had previ-
ously been preserved (RNAlater, Ambion), by using an
RNeasy mini kit (Qiagen), and was reverse-transcribed
into cDNA using a first-strand cDNA synthetase kit(Roche Diagnostics). Real-time qPCR protocols were
designed based on the MIQE guidelines and performed
using the SYBR Green technology on a LightCycler
rapid thermal cycler (Roche Diagnostics), in accordance
with the manufacturer’s instructions. Quantification re-
sults for mRNA levels for each target gene were normal-
ized to the geometric mean of the expression of three
optimal reference genes for the study of gene expression
in cardiac tissue (Rpl13a, Tbp and Ndc1). Evaluation of
reference genes and PCR primers employed is described
in Additional file 1.
Western blot analysis
Protein extracts from LV tissues were prepared by adding
ice-cold RIPA buffer supplemented with a protease inhi-
bitor cocktail (Roche, Basle, Switzerland), and homoge-
nised using a TissueLyser II (Qiagen). After centrifugation
(20 min, 16,500 × g, 4°C), protein concentrations of super-
natants were determined by BCA assay (Thermo Scien-
tific). Western blotting was performed as previously
described [9]. Briefly, 25 μg of each sample was loaded
onto a 12% Bis-Tris-polyacrylamide gel (Invitrogen) and
transferred to nitrocellulose membranes. Blots were
first probed with specific antibodies as follows: CTR1
(sc-66847, Santa Cruz Biotechnology Inc); CTR2 (sc-
104852, Santa Cruz Biotechnology Inc); MT1/2 (sc-11377,
Santa Cruz Biotechnology Inc), and then incubated with an
HRP-conjugated IgG, (dilution 1:10,000, Jackson Labora-
tories). Specific protein bands were detected by using an
enhanced chemiluminescent substrate (ECL Plus, GE
Healthcare, Buckinghamshire, UK) and imaged using an
LAS 3000 image reader (Fuji Photo Film Co. Ltd, Tokyo,
Japan). Ponceau-S staining was used as the reference for
loading controls, and band intensities were measured using
MultiGauge software v2.0 (Fuji Photo Film).
Cu/Zn-SOD1 ELISA
LV tissues were weighed and minced into small pieces
before homogenization in phosphate-buffered saline
(pH 7.2; 20 μl/mg tissue) using a TissueLyser II
(Qiagen). The resulting suspension was subjected to two
freeze-thaw cycles and then centrifuged (5 min, 5000 × g,
4°C). Thereafter, supernatants were removed and total-
protein concentrations determined by bicinchoninic acid
(BCA) assay (Thermo Scientific). SOD1 concentrations
were measured using an ELISA kit according to the
manufacturer’s protocol (USCN Life Science; Wuhan,
Hubei, PRC) by spectrophotometry (450 nm, microplate
reader; SpectraMAX 340, Molecular Devices; Sunnyvale,
CA), and the concentration of SOD1 (ng/mL) in the
sample supernatants calculated by comparing the O.D.
of the samples to a standard curve. Results were then
converted to ng/mg total protein and expressed as con-
centrations relative to the corresponding control group.
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LV tissues were homogenized in ice-cold 0.1 M Tris/
HCl, pH 7.4 containing 0.5% Triton X-100, 5 mM mer-
captoethanol and 0.1 mg/ml PMSF using a TissueLyser
II (Qiagen). The crude tissue homogenates were then
centrifuged (14,000×g, 5 min, 4°C) and the supernatants
collected: these contained total SOD activity from com-
bined cytosolic and mitochondrial sources. Following in-
cubation with 0.4 vol of a solution containing ethanol
and chloroform (25:15 vol/vol) to inactivate the mito-
chondrial SOD2 [59], mixtures were centrifuged at
5000 × g for 15 min and aliquots of the supernatant used
to measure protein concentration by BCA assay, and Cu/
Zn-SOD activity using the Superoxide Dismutase Activity
Assay kit (Abcam). The latter works by measuring the in-
hibition of the reduction of a water-soluble tetrazolium
salt (WST-1) which produces a water-soluble formazan
dye upon reduction by O2
●- radicals, which are generated
by xanthine oxidase and inhibited by SOD. One unit of
SOD activity is the amount necessary to inhibit the
xanthine oxidation by 50%. The IC50 (50% inhibition activ-
ity of SOD) was detected by a colorimetric method at
450 nm using an absorbance microplate reader (Spectra-
MAX 340, Molecular Devices) and the results expressed
per mg of total protein.
Immunofluorescence analysis of LV free-wall tissue
Immunofluorescent staining was performed using standard
techniques as described. Briefly, 6-μm LV sections frozen
in OCT were cut, fixed in acetone, and blocked with 5%
(vol/vol) normal donkey serum (NDS) in PBS. They were
then incubated overnight at 4°C with primary antibody in
5% NDS (vol/vol). Primary antibodies used in these experi-
ments were: anti-CTR1 (at 1:200 vol/vol final dilution,
Abnova); anti-CTR2 (1:50, Santa Cruz); MT1/2 (1:100,
Abcam); CCS (1:200, Novus Biologicals); ATOX1 (1:100,
Santa Cruz); ATP7A (1:250, Abcam), ATP7B (1:150, Novus
Biologicals), and N-cadherin (1:50, Abcam). Following 3 ×
washes with PBS, sections were incubated with appropriate
fluorescently-labeled (−FITC or -Rhodamine Red, as re-
quired) donkey anti-rabbit/mouse/chicken IgG secondary
antibodies (Jackson ImmunoResearch). After incubation,
sections were washed and incubated overnight with WGA-
Oregon Green 488 (1:5000; Molecular Probes) in PBS at
4°C. Finally, sections were washed again and mounted with
Prolong Gold anti-fade reagent with DAPI (Invitrogen).
The immunofluorescent images were captured at 40×, 60×
or 100× magnifications using a confocal fluorescent micro-
scope (Olympus FV1000, Fuji).
The fluorescently-labeled signals from each image
were processed and quantified using a custom-written
IDL analysis program based on signal-thresholding, as
previously described [9,10]. Briefly, the original image
was masked to exclude non-labeled areas. The thresholdfor quantifying fluorescent labeling was then established,
based on information in the masked image’s histogram
compared with the original image. The criteria for the
thresholding process were maintained equivalent across
all experimental groups. Results were expressed as per-
centages of corresponding total cross-sectional areas. To
avoid any possible confounding effect of orientation and
origin of the muscle fibers on the signal quantification,
at least five transverse optical-sectional images from
each section of the LV-myocardium, two sections from
each animal, and four animals per group, were analyzed.
Statistical analysis
Data have been expressed as mean ± SEM unless stated
otherwise. Significance of between-group differences was
determined by unpaired Student’s t-tests, one-way ANOVA,
or two-way ANOVA, as appropriate. The primary a priori
null hypothesis in each contrast was that there was no dif-
ference between signals from TETA-treated diabetic and
untreated diabetic states. A second between-group com-
parison was performed in each case, with the a priori null
hypothesis being that there was no difference between sig-
nals from control and diabetic animals: this latter contrast
was included to ensure that effects of diabetes were present
as a starting condition for comparison with TETA-treated
samples. Where stated in the figure legends, correction for
multiple-comparisons has been applied. All contrasts were
two-tailed, and values of P < 0.05 have been considered
significant.
Results
Diabetes caused myocardial copper deficiency that was
rectified by TETA treatment
LV-copper levels were markedly deficient (decreased
to ~50% of normal) after 16-weeks’ untreated diabetes.
Strikingly, LV-copper levels were fully restored to normal
(control) concentrations when TETA treatment was insti-
tuted after 8-weeks’ diabetes and maintained for a further
8 weeks (Figure 1A): this effect was accompanied by sub-
stantial improvements in cardiac function, including in
cardiac output, and indexes of systolic and diastolic func-
tion (Table 1). However, TETA treatment did not change
any index of cardiac function in non-diabetic control rats
(Table 1), consistent with previous reports [8,60].
TETA treatment accentuated diabetes-evoked up-
regulation of CTR2, whereas it did not modify diabetes-
elicited lowering of Ctr1 expression
Immunoblotting for the high-affinity copper transporter,
CTR1, indicated the presence of dimeric (~45 kD) and tri-
meric (~75 kD) forms, both of which were diminished in
diabetic LV myocardium as compared to control (Figure 1B
and 1C). TETA treatment did not restore CTR1 expres-

























































































































































Figure 1 Measurement of total myocardial copper content, and mRNA and protein levels of copper-uptake transporters CTR1 and
CTR2 in LV-tissue from control, diabetic and TETA-treated diabetic rats. A: Total myocardial copper concentrations (μg/g dry LV tissue)
measured by PIXE/RBS in LV sections. Values are means ± SEM; significance of differences has been analyzed by one-way ANOVA with Bonferroni’s
multiple-comparisons test: **P < 0.01, diabetic vs. control; ##P < 0.01, TETA-diabetic vs. diabetic: n = 7/group. B and C: Representative Western blots
for CTR1. The intensities of the CTR1 bands (~45 kD and ~70 kD, respectively) normalized to Ponceau-S-stained bands are depicted graphically.
D: Representative Western blot of CTR2. The total intensities of the CTR2 protein bands (~32 kD and ~64 kD) relative to Ponceau-S-stained bands
are depicted graphically. E: RT-qPCR analysis of Ctr2 mRNA levels. Results were normalized to a robust normalizer (geometric mean of mRNA levels
of Rpl13a, Tbp and Ndc). All data are means ± SEM and presented as relative to the respective controls, which were set at 1: *P < 0.05, **P < 0.01
vs. control and #P < 0.05 vs. diabetic: n = 7/group (B, C, D), and n = 9/group (E).
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protein levels were also unchanged in TETA-treated con-
trols (data not shown).
Confocal imaging was used to further investigate the
role of CTR1 in copper-deficient diabetic LV. CTR1 was
found to co-localize predominantly with the myocardial
T-tubule membrane system in control LV (Figure 2A);
however, CTR1 staining appeared to be diminished and
irregular in diabetic LV, consistent with possible disrup-
tion of the T-tubules themselves. TETA-treated diabetic
tissues may have a slightly more organized CTR1 stain-
ing localization as compared to untreated diabetes, al-
though this effect is subtle. In addition, quantitative
immunofluorescent analysis of CTR1 confirmed the
diminished staining intensity in both diabetic and TETA-
treated diabetic LV (Figure 2B). These results are consist-
ent with CTR1 immunoblotting data, and cumulatively
support the down-regulation of CTR1 as being a potentialmechanism of impaired copper uptake and subsequent
copper deficiency in diabetic LV.
As TETA treatment did not restore CTR1 protein ex-
pression in diabetes, it seemed unlikely that this could be a
mechanism by which TETA restores LV-copper levels.
Interestingly, immunoblotting for the lower affinity-copper
transporter, CTR2, showed increased expression of both
dimeric (~32kD) and tetrameric (~64 kD) CTR2 forms
in diabetic LV (Figure 1D). CTR2 is known to form func-
tional homo-multimers and the specificity of bands was
verified here by antibody blocking (data not shown). Fur-
thermore, Ctr2 mRNA was also increased in diabetic LV as
compared to control (Figure 1E). Further studies showed
that, unlike CTR1, TETA treatment significantly elevated
CTR2 expression, although rather than merely restoring
levels, it further increased both Ctr2 mRNA and pro-
tein expression as compared to untreated diabetic LV

































Figure 2 Immunofluorescent analysis of CTR1 localization in LV sections from control, diabetic and TETA-treated diabetic rats.
A: Representative LV-wall longitudinal sections (100 ×-objective) labeled with anti-CTR1 (red) and WGA (green): n = 40 sectional images/group:
scale bar = 20 μm. For further magnified images, scale bar = 4 μm. B: Quantitative analysis of immunofluorescent-signal area for CTR1. Confocal
images (40 ×-objective) were analyzed using a custom-written IDL analysis program based on signal-thresholding. Results are expressed as mean
of the percentages of corresponding cross-sectional areas: **P < 0.01 vs. control: at least 40 sectional images/group were analyzed.
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shown). These results are consistent with an increase of
copper uptake via CTR2 as a key part of the mechanism
by which TETA restores myocardial copper content.
We employed confocal imaging to further examine the
role of CTR2. Transverse sections of LV showed CTR2 lo-
calized to the nucleus and intracellular vesicles of myo-
cytes, along with subtle staining of the sarcolemmal
membrane in controls. This staining pattern was more in-
tense in diabetic LV, particularly in the intracellular small
vesicles, from which copper is known to translocate to
the cytosol (Figure 3A). This response correlates well to
enhanced CTR2 protein expression, which could repre-
sent an endogenous, self-compensating response towards
maintenance of cytosolic copper in diabetes. Interestingly,
LV from TETA-treated animals showed further increases
in CTR2 staining at or near the outer sarcolemmal mem-
brane: increased expression of CTR2 in this location could
well mediate enhanced uptake of extracellular copper
into cardiomyocytes. Moreover, longitudinal LV sections
confirmed enhanced staining of CTR2 at the cardio-
myocyte periphery, particularly at the intercalated discs
of TETA-treated diabetic LV (as compared to controland untreated-diabetic LV) (Figure 3B), consistent with
increased transport of copper between neighboring myo-
cardial cells. Co-staining of N-cadherin with anti-CTR2
confirmed the intercalated disc localization (Figure 3C). In
addition, the enhanced localization of CTR2 at the outer
sarcolemmal membrane in TETA-treated LV is a candi-
date mechanism by which TETA could enhance copper
uptake and restore LV copper content.
Diabetes lowered the expression of MT1 and MT2 in LV
myocardium
Deficient myocardial-copper levels could be associated
with altered expression or function of intracellular copper-
regulating proteins. We therefore examined the expression
of the copper-binding proteins, MT1 and MT2, which act
to maintain low levels of free transition-metal ions (par-
ticularly Cu and Zn) within cells, and play essential roles
in copper-ion detoxification [61]. RT-qPCR demonstrated
a significant reduction in mRNA levels of Mt1 and Mt2 in
diabetic LV compared with control tissue (Figure 4A and
4B), and TETA treatment did not reverse these changes.
The lower levels of Mt1 and Mt2 mRNAs observed in dia-














Figure 3 Immunofluorescent micrographs of CTR2 localization in sections of the LV free-wall from control, diabetic and TETA-treated
diabetic rats. A: Representative LV wall cross-sections (100 ×-objective) labeled with anti-CTR2 antibody (RRX red). Arrows indicate ‘vesicle-like’
structures adjacent to the sarcolemmal membrane. B: Representative longitudinal sections of LV-wall (100 ×-objective) labeled with anti-CTR2
antibody (red). Arrows indicate intercalated disks. All sections in A and B were co-stained for sarcolemmal membranes (green) and nuclei (blue)
with WGA-Oregon Green 488 and DAPI, respectively: n = 40 sectional images/group: scale bar = 20 μm. C: Representative double-immunofluorescent
labeling of CTR2 and N-cadherin in longitudinal LV sections (60×-objective). Arrows indicate co-localization at the intercalated disk: n = 10 sectional
images/group: scale bar = 30 μm.
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and Mt2 is known to be primarily regulated by intracellu-
lar metal concentrations at the level of transcription [61].
Confocal micrographs of control LV stained for com-
bined MT1/2 showed intense sarcoplasmic and nuclear
localization, with lower-intensity staining of the sarcolem-
mal membrane (Figure 4C). MT1/2 staining intensity was
notably diminished in both untreated and TETA-treateddiabetic cardiomyocytes, with some stronger staining per-
sisting near the sarcolemmal surface. Quantification of the
fluorescent signal area confirmed diminished staining in-
tensity of MT1/2 in diabetic and TETA-treated diabetic
LV as compared to control (Figure 4D). Furthermore, no
notable change in the localization of MT1/2 signal inten-
sity was detected in diabetic or corresponding areas of










































































Figure 4 mRNA levels and percentages of protein signal-areas corresponding to MT1/2 in LV tissues from control, diabetic and TETA-treated
diabetic rats. A and B: RT-qPCR analysis of Mt1 and Mt2 mRNA levels. All data are means ± SEM and presented relative to their respective controls,
which were set at 1: n = 9/group. C: Representative confocal images of immunofluorescent-stained cross-sections of LV (40 ×-objective) labeled with
anti-MT1/2 (red), WGA-Oregon Green 488 for sarcolemmal membrane (green), and DAPI for nuclei (blue). At least five images/section, two sections/
animal, and four animals/group were examined: scale bar = 50 μm. D: Quantification of immunofluorescent-labeled myocardial signals areas for MT1/2.
Results are means ± SEM and presented as the percentages of corresponding cross-sectional areas. At least five transverse optical sectional images/
section, two sections/animal and four animals/group were analyzed: n = 40 sectional images/group: *P < 0.05, **P< 0.01 vs. control.
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thus decreased protection against copper toxicity in
diabetes.
Increased polymerization of MT in diabetic rats was
partially ameliorated by TETA treatment
Oxidation of the sulfhydryl groups in MT can lead to
their polymerization and altered copper-binding proper-
ties. Western blotting of LV did not detect monomeric
MT1/2, but instead several higher molecular-weight bands
of ~30, 45 and 70 kD in all 3 treatment groups (Figure 5A)
(specificity of MT bands was verified by antibody blocking
studies, data not shown). Combined densitometry of all 3
polymerized MT bands indicated a reduction of ~34% ex-
pression in diabetes whichTETA treatment did not signifi-
cantly alter (Figure 5A), consistent with the lowering in
the MT immunofluorescent signal shown above.
However, densitometry of the respective MT band
sizes revealed that ~70 kD MT was significantly in-
creased, by ~50%, in diabetic LV tissue (Figure 5B),
whereas the ~45kD and ~30 kD bands were significantly
reduced, by 48% and 40% respectively, in diabetic LV as
compared to control (Figure 5C and 5D). Interestingly,
TETA treatment partially corrected diabetes-induced
changes in the expression of all 3 polymerized MTbands (Figure 5B, 5C and 5D). These results provide
clear evidence that TETA treatment could result in de-
creased polymerization of MT, which is consistent with
decreased oxidative stress in the TETA-treated diabetic
heart.
TETA rectified diabetes-mediated defects in CCS and SOD1
CCS delivers copper to the apoenzyme of SOD1 to yield
the active holoenzyme. RT-qPCR demonstrated CcsmRNA
levels were significantly down-regulated, by ~30%, in
diabetic LV compared with control tissue (Figure 6A).
Interestingly, TETA treatment reversed this decrease in
mRNA expression to levels similar to non-diabetic con-
trol values. Furthermore, quantitative immunofluores-
cent analysis showed that diabetic LV had decreased
CCS-specific signal areas, which were normalized by
TETA treatment (Figure 6B). These results show that
transcriptional and translational dysregulation of CCS
occurs in diabetes and is rectified by TETA treatment.
As the down-regulation of CCS in diabetes could well
impair its ability to deliver copper to SOD1, we investi-
gated whether SOD1 activity was altered in diabetes. In-
deed, SOD1 activity was significantly decreased in diabetic
LV, whilst TETA-treated diabetic tissue showed restor-





























































































































Figure 5 Representative Western blots of LV extracts probed for anti-MT1/2. The intensities of the immunoreactive MT1/2 protein bands
(A, B, C, D for total, ~70 kD, ~45 kD and ~ 30 kD polymerized forms of MT1/2, respectively) normalized to corresponding Ponceau-S-stained
bands and depicted graphically. Quantitative data are means ± SEM and presented as relative to the non-diabetic controls, which were set at





































































































Figure 6 Expression and activity analyses of CCS and SOD1 in LV tissues from control, diabetic, and TETA-treated diabetic rats.
A: RT-qPCR analysis of Ccs mRNA levels. Data are means ± SEM and presented relative to the respective controls which were set at 1: **P < 0.01,
vs. control; ##P < 0.01 vs. diabetic: n = 9/group. B: Quantitative analysis of immunofluorescent signal area for CCS. Results are expressed as means
of the percentages of corresponding cross-sectional areas. At least 40 sectional images/group were analyzed: **P < 0.01 vs. control; ##P < 0.01 vs.
diabetic. C: Measurement of SOD1 activity by monitoring xanthine oxidase activity, which is inhibited by SOD1. The IC50 (50% inhibition activity of
SOD) was detected by a colorimetric method at 450 nm and the results calculated as units/mg of total protein (based on a unit of SOD activity
as the amount necessary to inhibit xanthine oxidation by 50%): **P < 0.01 vs. control; ##P < 0.01 vs. diabetic: n = 9/group. D: Measurement of
protein levels of SOD1 in LV extracts by ELISA. Results were calculated as ng/mg total protein and are presented as the means of relative
concentrations related to the control group, which was set at 1: **P < 0.01 control: n = 9/group.
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myocardium compared to control values, which TETA
treatment did not restore (Figure 6D), although no detect-
able between-group differences in Sod1 mRNA levels
were present (data not shown). These results indicate that
SOD1 is subject to post-transcriptional down-regulation
in diabetic LV tissue. We also found that TETA had no de-
tectable effects on SOD1 expression in diabetic LV tissue
(Figure 6D). These results, when taken together, indicate
that decreased expression of SOD1 and CCS contribute to
the deficiency in LV-myocardial SOD1 activity in diabetes.
They also indicate that TETA treatment activates SOD1
by increasing the supply of copper for incorporation into
the enzyme via improved CCS function, without changing




























































































Figure 7 Expression of analysis of ATOX1, ATP7B and ATP7A in LV tis
Quantitative analysis of immunofluorescent signal area for protein signals o
the percentages of corresponding cross-sectional areas. At least 40 section
analysis for mRNA levels of Atp7a. Data are means ± SEM and presented re
diabetic: n = 9/group. D: Quantitative analysis of immunofluorescent signal
percentages of corresponding cross-sectional areas. At least 40 sectional im
confocal images (60 ×-objective) of transverse LV-wall sections labeled with
Golgi-network structure: n = 40 sectional images/group: scale bar = 30 μm.Diabetes and TETA treatment evoked different responses
in the regulation of the copper-transporting ATPases
ATP7A and ATP7B
Copper supply to ATP7A and ATP7B is mediated by the
copper-chaperone protein ATOX1, which binds to and
transports copper to compartments containing the target
ATPases. In light of their roles in copper regulation, we
investigated the myocardial expression of these three
proteins. We found no significant changes in the mRNA
levels of Atox1 or Atp7b in diabetic or TETA-treated
diabetic LV compared to control (data not shown). How-
ever, quantitative immunofluorescence of signal areas of
ATOX1 and ATP7B, demonstrated that both were de-
creased in diabetic LV, and remained so following TETA
















sues from control, diabetic and TETA-treated diabetic rat. A and B:
f ATOX1 and ATP7B, respectively. Results were expressed as mean of
al images/group, have been analyzed: **P < 0.01 vs. control. C: RT-qPCR
lative to the respective controls, which were set at 1. ##P < 0.01 vs.
area for ATP7A-protein. Results have been expressed as means of the
ages/group, were analyzed: ##P < 0.01 vs. diabetic. E: Representative
anti-ATP7A antibody (red). Arrows indicate the peri-nuclear stain and
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all treatment groups showed that ATP7B localizes in the
nuclear/peri-nuclear region (presumably in the trans-
Golgi network), and also with the T-tubules (Figure 8A)
and intercalated disks (as indicated by co-staining with
N-cadherin) (Figure 8B). Comparative staining of ATP7B
in all 3 treatment groups showed that, in control trans-









Figure 8 Immunofluorescent micrographs of ATP7B localization in se
diabetic rats. A: Representative confocal images (100 ×-objective) of LV-w
Sections were co-stained for sarcolemma (green) and nuclei (blue) with WG
co-staining of nuclei and ATP7B: scale bar = 20 μm. The more highly magn
scale bar = 4 μm. B: Representative confocal images (60 ×-objective) of lon
(green). Arrows indicate co-staining at the intercalated disk: scale bar = 30 μ
LV-wall sections labeled with anti-ATP7B antibody (red), WGA (green), and D
vesicles: scale bar = 50 μm: n = 40 sectional images/group.nuclear and peri-nuclear regions, but this nuclear stain-
ing was diminished in diabetic and TETA-treated dia-
betic LV. Instead, diabetic and TETA-treated diabetic LV
had a more striking vesicular localization in the sarco-
plasm, which in places was close to the sarcolemmal
membrane (Figure 8C). The diminished expression and
altered localization of ATP7B, combined with lowered










ctions of the LV free-wall from control, diabetic and TETA-treated
all longitudinal sections labeled with anti-ATP7B antibody (red).
A-Oregon Green 488 and DAPI, respectively. Arrows indicate the
ified images show co-localization of ATP7B and T-tubule membranes:
gitudinal LV-wall sections labeled for ATP7B (red) and N-cadherin
m. C: Representative confocal images (40 ×-objective) of transverse
API (blue). Arrows indicate nuclear/peri-nuclear and sarcoplasmic
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from the cell/between cells, providing a putative mech-
anism for reversing the localized copper imbalances that
may occur in diabetic myocardium.
By contrast, the mRNA levels and quantitative immuno-
fluorescent signal areas for ATP7A were both unaltered in
diabetic LV as compared to control, whereas TETA-treated
diabetic LV showed significantly increased ATP7A levels,
implying transcriptional and translational up-regulation
(Figure 7C and 7D), consistent with TETA-elicited al-
terations in rates of copper trafficking via ATP7A in the
secretory pathway. Confocal micrographs of transverse
sections showed that, in control LV, ATP7A was mainly
localized to the peri-nuclear region and also showed ves-
icular staining throughout the sarcoplasm which may rep-
resent the intracellular trans-Golgi network membranes
(Figure 7E). No notable changes in ATP7A localization
in diabetic LV were apparent, whilst TETA-treated dia-
betic LV showed significantly enhanced vesicular and
peri-nuclear staining intensity (correlating to quantita-
tion). These results imply activation of copper trans-
location by ATP7A in the secretory pathway, which
could lead to improve utilization of copper by cuproen-
zymes in the secretory compartments in response to
TETA treatment.
Discussion
Here we report that a marked deficiency in total copper,
of ~50%, occurred in the LV myocardium of diabetic rats
with DCM and, strikingly, that there was full restoration
of copper to control levels following treatment with the
Cu (II)-selective chelator, TETA, [8,48]. We also demon-
strate that TETA-mediated restoration of LV copper was
accompanied by marked improvement in the structural
and functional defects in the LV of rats with DCM, con-
sistent with prior reports [8,48,60]. TETA treatment with
the dosage used for the current protocol did not have any
adverse effects on cardiac function in non-diabetic control
LV, although long-term treatment with higher dosages
could be expected to cause symptomatic copper deficiency
[62]. We also identified several myocellular copper pro-
teins that respond to TETA treatment in diabetes, but
TETA treatment in non-diabetic controls did not alter ex-
pression of copper transporters CTR1 and CTR2. There-
fore TETA treatment at the dosage employed does not
affect copper transport, and further data from TETA-
treated non-diabetic controls are not required for inter-
pretation of results of the current study. One question
that then arises from these data is that of how copper-
chelation successfully ameliorates LV copper deficiency
in diabetes?
Physiological copper exists in the body in two valence
states, Cu (I) which is mainly localized in the intracellular
compartment and comprises ~95% of total body-copper,and Cu (II), which is largely present in the extracellular
space and comprises the remaining ~5% [63]. We report
here that diabetic rats have lower myocardial copper, a re-
sult mainly of decreased intracellular Cu (I), whereas we
have shown previously that chelatable extracellular cardiac
Cu (II) is increased by ~3-fold in diabetic rats [8]. These
results support the hypothesis that the copper-deficient
state in the diabetic LV-myocardium is associated with in-
sufficient [Cu (I)]IC but excessive [Cu (II)]EC: that is, it re-
flects an imbalanced distribution of myocardial copper
consistent with defective copper uptake into the LV.
Heart failure in diabetes may thus be explained, at least
in part, by disruption of the distribution of the two cop-
per valence states, and the concomitant myocardial
damage that ensues.
Elevated [Cu (II)]EC is thought to promote the increased
formation of advanced glycated end-products (AGEs) in
collagen, and enhanced TGF-β-evoked collagen deposition
[12]. TETA is a selective Cu (II) chelator [45,64] that binds
free copper, thus suppressing Cu (II)-catalyzed reactions
of reactive oxygen species, such as O2
●- or H2O2, to gener-
ate HO● radicals in the ECM [55]. Therefore, the improve-
ment in cardiac structure and function caused by TETA
treatment may ultimately be evoked, at least in part, by
the rebalancing of the intracellular-to-extracellular ratio of
the copper valence states. However, little is known of
the molecular basis for regulation of relative myocardial
Cu (I)/Cu (II) distribution. The molecular mechanisms
through which TETA may correct this imbalance were
thus a major focus of this study.
Normal cardiac structure and function is reportedly
sensitive to marginal copper deficiency: as copper defi-
ciency worsens, the heart is said to become more sus-
ceptible to oxidative damage through impairment of its
copper-dependent defense mechanisms, such as those
catalyzed by SOD1 [25]. Here we have investigated the
mechanisms through which impaired cellular copper
regulation could alter the biology of proteins in the cop-
per pathways and their potential influence on the LV
myocardium. We have provided compelling evidence
for dysregulation of cellular copper pathways in the LV
in DCM. Key alterations include: (i) decreased expres-
sion of the high-affinity copper transporter CTR1; (ii)
decreased expression and increased polymerization of
the copper-binding/anti-oxidant defense proteins MT1/
2; (iii) decreased levels of CCS and SOD1, coupled with
diminished SOD1 activity; (iv) decreased expression of
ATOX1 and ATP7B, which could well impair copper trans-
port to sites of synthesis of copper-enzymes within the
secretory pathway; and (v) translocation of ATP7B, which
may alter copper efflux from or between cardiomyocytes.
The diminished expression of myocardial CTR1 pro-
tein levels provides a potential mechanism for localized
copper deficiency in the diabetic LV. Unaltered Ctr1
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deficiency may well be generated at a translational rather
than transcriptional level. The findings of deficient total
copper (mainly Cu (I)) in the LV coupled with substantively
diminished CTR1 at the cell membrane, and with increased
internalisation and lowered overall levels of the transporter,
are consistent with a mechanism known to occur in several
mammalian cell types, namely copper-evoked endocytosis
[65,66] and degradation [65]: these findings are consistent
with the presence of elevated Cu (II) in the ECM of the
coronary vasculature in the diabetic heart, which could well
trigger this defect [8] and thus cause heart failure in dia-
betes [16]. The disorganised pattern of CTR1 distribution
in the T-tubular region of the diabetic LV is also note-
worthy. Consistently, it has been reported that ventricular
myocytes from diabetic animals with heart failure possess a
sparse, irregular T-tubule system [67]: it is possible that this
disorganization could contribute to impaired myocardial
copper uptake. Furthermore, the T-tubules are an import-
ant determinant of cardiomyocyte function, especially as
they are the main site of excitation-contraction coupling
[10]. Therefore the observed structural changes at this sub-
cellular site of CTR1 localization may point to a link be-
tween defective myocardial copper uptake and impaired
myocardial contractility [9,10], implying a potential role
of myocellular copper homeostasis in the regulation of
excitation-contraction coupling: however, myocellular
copper currently has no known role in myocardial
excitation-contraction coupling [39]. By contrast, since
TETA treatment did not correct diminished CTR1 levels
in diabetes, CTR1 is unlikely to play a role in the TETA-
evoked correction of LV copper levels and function.
Contrastingly, TETA treatment increased the expression
of Ctr2mRNA and protein compared to untreated diabetic
values but not to untreated control values, suggesting the
effects of TETA on these pathways occurred only in dia-
betes. TETA treatment also enhanced CTR2 localization at
the cell periphery, specifically at the outer sarcolemmal
membrane and the intercalated disk region, where it could
increase copper uptake from the extracellular space and
neighboring cardiomyocytes, respectively. Therefore, eleva-
tion of CTR2 is a candidate mechanism whereby TETA
can restore copper levels in diabetic LV. There is evidence
that cells possess more than one copper uptake pathway.
Thus, dietary copper supplementation of pregnant mice
did not rescue Ctr1−/− offspring, suggesting that Ctr1−/−
embryos cannot acquire copper because of the lack of the
plasma membrane CTR1 transporter; however, CTR1-
deficient mouse embryonic cells possess a second, CTR1-
independent copper transport system [68]. CTR2 localizes
in part to the cell membrane, and cells lacking CTR2
have lower copper accumulation [69]. Therefore, al-
though CTR2 is a lower-affinity copper transporter than
CTR1, TETA may nevertheless correct LV-copper levelsby up-regulating CTR2, thereby increasing copper import.
Moreover, TETA-evoked increase in the sarcolemmal
localization of CTR2 contrasts with the observed enhance-
ment of CTR2 localization in the vesicular compartments
in diabetic LV: a vesicular localization for CTR2 has previ-
ously been reported, where it was noted to co-localize with
both lysosomes and late endosomes [70]. Diabetes-
mediated elevations in CTR2 expression in vesicular
membranes are possibly the endogenous compensatory re-
sponse by which copper released from copper proteins by
lysosomal degradation is recycled into the cytosol and thus
made available for cellular utilization in response to low-
ered copper uptake by CTR1: this could happen without
changing total cellular copper levels. Moreover, the ele-
vated recycling of copper into the cytosol via CTR2 could
also serve as a signal of increasing intracellular copper
levels, in turn further lowering copper uptake by CTR1.
Thus CTR2 and CTR1 show opposing changes in expres-
sion and thus, quite possibly, opposing roles in diabetes-
induced LV-copper deficiency. Lastly, our findings in
diabetic rats contrast with the lowered expression of
CTR2 in the hearts of rats with diet-induced systemic
copper-deficiency [71]: this contrast points to a distinct
pathogenic mechanism in the regulation of copper up-
take in the LV myocardium of the diabetic rat in the
context of the overall systemic copper overload that oc-
curs in diabetes [8,45].
Metallothioneins are one of the major classes of copper-
binding proteins contributing to the regulation of intracel-
lular copper homeostasis and protection against excess
cytoplasmic copper [61,72], acting through their actions as
a scavenger of transition metal atoms and radicals [72].
Previous studies have implied that oxidative stress induced
by chronic hyperglycemia can impair intracellular copper
homeostasis in the diabetic heart, in part by suppressing
myocardial MT expression [61,73]. Here, we detected de-
creased expression but increased polymerization of MT in
diabetic myocardium which may lead to decreased avail-
ability of redox-responsive forms of MT, and thus to de-
creased protection against copper-mediated toxicity. The
lowering of total MT will lead to a concomitant reduction
in cytoplasmic copper-binding capacity, which is consist-
ent with the lowered intracellular copper levels we ob-
served, most likely attributable to reduced CTR1-mediated
copper influx. The decreased expression of the highly po-
lymerized, ~70-kD isoform of MT present after TETA
treatment is consistent with the decrease in levels of
copper-containing MT associated with decreased cellular
oxidation. This finding correlates with improved func-
tional activities of MT, and is consistent with a process of
MT-mediated correction in myocardial cytoplasmic cop-
per levels.
Here we also found evidence of decreased copper sup-
ply to SOD1 via CCS in diabetic myocardium, which
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The catalytic function of SOD1 is dependent on copper
redox chemistry at its active site, and is thus potentially
regulated by rates of cellular copper supply: the observed
relative inactivity of SOD1 in diabetic myocardium is con-
sistent with deficient copper metalation of apo-SOD1. It
has been reported that SOD1 with lowered copper content
is less catalytically active, and may also be unstable and de-
graded faster than the normally-metalated enzyme [74].
The decreased activity of SOD1 could lead to diminished
anti-oxidant protection thus enabling enhanced oxidative
damage in the diabetic LV-myocardium. In contrast to
other reports showing up-regulation of CCS protein
caused by dietary copper-deficiency in rats [75], our study
demonstrates lowered levels of CCS in copper-deficient
LV myocardium, consistent with a contrasting role of CCS
in response to the changes of copper status under diabetic
conditions. TETA treatment rectified CCS levels and the
activity of SOD1, consistent with restoration of copper-
supply to SOD1 via CCS, reversing deficient SOD1
activity, and contributing to demonstrated restoration of
myocardial anti-oxidant defenses [60].
ATP7A and ATP7B contribute to the maintenance of
copper-dependent enzyme activity by delivering copper
to the lumen of the secretory pathway in the trans-
Golgi network, where copper metalation generates ac-
tive cuproenzymes. These ATPases can also contribute
to the maintenance of intracellular copper concentra-
tions by transporting copper into secretory vesicles
from the trans-Golgi network, which shuttle to the
plasma membrane for copper excretion [76]. Here we
found that, in diabetic LV, protein levels of both ATOX1
and ATP7B were decreased, consistent with possible
impairment of copper supply for activation of cupro-
enzymes. The decreased localization of ATP7B to the
sarcolemmal membrane and intercalated disc regions in
diabetes could limit intercellular transport of copper.
Cumulatively these mechanisms could contribute to the
pattern of copper deficiency and impaired cardiac func-
tion [9,10]. We also found that the ATP7A copper
transporter, which is thought to function mainly in in-
testinal copper acquisition [39], is expressed in the myo-
cardium. TETA enhanced the expression of ATP7A
mRNA and protein, which could compensate and help
to rectify impaired copper delivery to the secretory
pathway/intercellular transport by defective ATP7B ac-
tion. These effects could contribute to the restoration
of physiological copper homeostasis and biosynthesis
of active copper-dependent enzymes in the myocar-
dium, in parallel to the TETA-mediated restoration of
the CCS-SOD1 pathway. The observed up-regulation
of ATP7A with enhanced peri-nuclear localization
following TETA treatment is consistent with en-
hanced delivery of copper to the trans-Golgi network,presumably aiding copper supply for newly-synthesized
copper proteins.
Some of the observed abnormalities, for example low-
ered levels of CTR1, CCS and SOD1, probably contrib-
ute to the causation of the localized copper-deficiency
state in diabetic myocardium or to its adverse conse-
quences, and thus to the functional impairment ob-
served in the hearts of diabetic animals [8,45,48]; other
effects, such as elevated CTR2 and lowered MT1/2 and
ATP7B, may reflect endogenous responses directed to-
wards ameliorating copper deficiency or its impacts.
How might TETA exert its intracellular effects? We
have previously shown that TETA selectively binds excess
Cu (II) in diabetic individuals and elicits its removal from
the body via urinary excretion, through studies where the
following methods were applied: electron paramagnetic
resonance spectroscopy; X-ray crystallography; potentio-
metric, spectrophotometric and mass-spectrometric ana-
lysis of complex formation between Cu (II), and TETA
and its metabolites; and clinical studies [8,45,55,64]. Thus
TETA can remove excess Cu (II) from the ECM, probably
by binding and removing it from pathogenic binding sites
such as those in AGE-modified collagen [77,78]. AGE-
coordinated Cu (II) almost certainly remains catalytically
active, and could therefore bind to the external, high-
affinity Cu (II)-binding site present near the NH2-terminus
of CTR1 [79]. Thus, elevated Cu (II) bound to AGE-
modified collagen in diabetic individuals could participate
in the modulation of cell copper metabolism through
binding to CTR1, perhaps resulting in its translocation
away from the cell membrane as shown herein. However,
TETA is also known to cross cell membranes, probably
via mechanisms employed by its physiological homo-
logues, spermine and spermidine [80]. For example, there is
substantive evidence that TETA can traverse cell
membranes in the gut and kidney via a Na+/spermine-
antiporter-mediated mechanism [81]. It thus has the
potential to exert direct effects in the intracellular
compartment.
TETA forms two main metabolites in the body,
monoacetyl-TETA and diacetyl-TETA [54,82-85]. Both
acetyl metabolites are strong chelators in their own
right, although their affinities for Cu (II) are substantially
less than that of the parent compound [64]. There is evi-
dence that monoacetyl-TETA may contribute to the
overall response to treatment in diabetic patients [84].
There are no published reports known to us, however,
describing the uptake of TETA directly into cardiomyo-
cytes, so whether TETA and its metabolites could act
directly within the intracellular compartment to influ-
ence copper homeostasis remains to be determined.
These studies have also provided a new molecular ex-
planation linking the therapeutic effects of TETA in dia-
betes to the restoration of myocardial copper content.
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TETA treatment, whose amended expression/activity re-
store antioxidant defenses, which include: (i) decreasing
the polymerization of MT1/2, consistent with dimin-
ished pro-oxidant stress; (ii) restoring LV-myocardial
copper uptake, at least in part via increased expression
of CTR2 in the sarcolemma; (iii) increasing copper sup-
ply to SOD1 via increased expression of CCS, leading to
restoration of SOD1 function; (iv) increasing expression
and localization of ATP7A in the trans-Golgi region, by
which it could improve copper translocation into the
lumen of the secretory pathway for synthesis of active
cuproenzymes. Our results indicate that hyperglycemia-
induced cell-copper imbalance in cardiomyocytes might
be rectified by TETA treatment via increased sarcolem-
mal copper importation coupled with compensatory
modifications in the export pathway. Cu (II)-chelation
with TETA treatment could thus allow the (partial) restor-
ation of copper delivery to intracellular sites of utilization
and storage.
Conclusions
In conclusion, we have identified for the first time, a
diabetes-induced process that impairs myocellular copper-
transport, leading to severe localized copper deficiency in
the LV-myocardium. This myocardial copper deficiency
elicits severe LV dysfunction that leads to DCM, which is
reversed by TETA treatment in the model we employed
here. Our parallel investigations in patients with LV hy-
pertrophy and diastolic dysfunction caused by type-2
diabetes, have indicated that a similar process probably oc-
curs in humans with DCM, who show signs of systemic
copper overload [45], and in whom excessive LV mass was
markedly improved by TETA treatment [8,48].We also
show here that this newly-recognized pathway can serve
as a target for drug discovery. For example, TETA treat-
ment normalized myocardial copper content and could
thus contribute to the maintenance or restoration of nor-
mal myocardial function in diabetes, by restoring myo-
cellular copper transport and antioxidant defenses. Our
findings provide a worked example for targeting a newly-
recognized myocardial copper transport pathway for
pharmaceutical discovery, using an approach based on
highly-selective Cu (II) chelation, which is shown here to
restore several defective, myocardial copper-trafficking
processes that would otherwise conspire to cause DCM
and heart failure. These findings have the potential to alter
the management of DCM.
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